Updated Results of the Phase I BALLI-01 Trial of UCART22 Process 2 (P2), an Anti-CD22 Allogeneic CAR-T Cell Product Manufactured By Cellectis Biologics, in Patients with Relapsed o... von Jain, Nitin, Chevallier, Patrice, Liu, Hongtao, Schiller, Gary J., Méar, Jean-Baptiste, DeAngelo, Daniel J., Curran, Kevin J, Grupp, Stephan, Baruchel, Andre, Balsat, Marie, LaCroce, Alexandra, Roudet, Caroline, Korngold, Ana B., Newhall, Kathryn J., Laille, Eric, Lee, Daniel J., Frattini, Mark G., Larson, Richard A., Boissel, Nicolas

Volltext

Abstract 1515: Hotspot mutations in KRAS and TP53 targeted by TCR-T cells genetically modified with the Sleeping Beauty transposon/transposase system von Korngold, Ana B., Yong, Lin-Kin, Zhang, Ming, Ibekwe, Ugochi, Hurton, Lenka V., Shi, Yaoyao, Simmons, Julissa, Collinson-Pautz, Matthew R., De Groot, Eleanor, Cooper, Laurence J., Deniger, Drew C.

Volltext

Abstract A179: Ex vivo generation of clinical grade T cells by using activating and propagating feeder cells to cross-link T cell receptor von Jena, Bipulendu, Taguchi, Hiroaki, Nowicka, Aleksandra, Korngold, Ana B., Huls, Helen, Cooper, Laurence JN

Volltext